BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2010; 19(5): i doi: 10.1002/pds.1850
2
Jinliang Chen, Yichao Xu, Honggang Lou, Bo Jiang, Rong Shao, Dandan Yang, Yin Hu, Zourong Ruan. Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic PredictionEuropean Journal of Drug Metabolism and Pharmacokinetics 2020;  doi: 10.1007/s13318-020-00647-z
3
Jing Gao, Jun Zhou, Yanyan Li, Ming Lu, Ru Jia, Lin Shen. UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patientsMedical Oncology 2013; 30(3) doi: 10.1007/s12032-013-0604-x
4
Sarah Allegra, Jessica Cusato, Silvia De Francia, Filomena Longo, Elisa Pirro, Davide Massano, Valeria Avataneo, Amedeo De Nicolò, Antonio Piga, Antonio D’Avolio. The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patientsThe Pharmacogenomics Journal 2019; 19(5): 417 doi: 10.1038/s41397-019-0071-7
5
Xin Jin, Meng-lin Jiang, Zhao-Hui Wu, Yu Fan. Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic TestingCurrent Medicinal Chemistry 2020; 27(14): 2322 doi: 10.2174/0929867326666190204123101
6
XiaoXia Wei, JiaQin Cai, Hong Sun, Na Li, Chenxia Xu, Guifeng Zhang, Yuxia Sui, Jie Zhuang, Bin Zheng. Cost–effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patientsPharmacogenomics 2019; 20(4): 241 doi: 10.2217/pgs-2018-0138
7
Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec. Intérêt du génotypage de l’UGT1A1 dans le cadre du traitement des cancers digestifs par irinotécanBulletin du Cancer 2014; 101(6): 533 doi: 10.1684/bdc.2014.1933
8
Sharon Marsh, Janelle M Hoskins. Irinotecan pharmacogenomicsPharmacogenomics 2010; 11(7): 1003 doi: 10.2217/pgs.10.95
9
Ann K. Daly. Current Concepts in Drug Metabolism and ToxicologyAdvances in Pharmacology 2012; 63: 137 doi: 10.1016/B978-0-12-398339-8.00004-5
10
Mafalda M Dias, Ross A McKinnon, Michael J Sorich. Impact of theUGT1A1*28allele on response to irinotecan: a systematic review and meta-analysisPharmacogenomics 2012; 13(8): 889 doi: 10.2217/pgs.12.68
11
J Cusato, S Allegra, D Massano, S De Francia, A Piga, A D'Avolio. Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectivenessThe Pharmacogenomics Journal 2015; 15(3): 263 doi: 10.1038/tpj.2014.65
12
Yuwei Yang, MengMeng Zhou, Mingjun Hu, Yanjie Cui, Qi Zhong, Ling Liang, Fen Huang. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysisAsia-Pacific Journal of Clinical Oncology 2018; 14(5): e479 doi: 10.1111/ajco.13028
13
L. Faugeras, A. Dili, A. Druez, B. Krug, C. Decoster, L. D’Hondt. Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancyCritical Reviews in Oncology/Hematology 2017; 115: 59 doi: 10.1016/j.critrevonc.2017.03.029
14
Katsuya Makihara, Sayaka Azuma, Nobuyuki Kawato, Hiroyuki Ueno, Izumi Nakata. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosageCancer Chemotherapy and Pharmacology 2015; 75(2): 273 doi: 10.1007/s00280-014-2633-3
15
John Logan Black. Molecular Diagnostics2014; : 35 doi: 10.1007/978-1-4614-8127-0_4
16
Lucía Cortejoso, Luis A López-Fernández. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patientsPharmacogenomics 2012; 13(10): 1173 doi: 10.2217/pgs.12.95
17
Xu Ma, Sen Han, Ying Liu, Jing‐Tao Liu, Jian Fang, Yan‐Hua Zhang. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan‐based chemotherapy in Chinese populationsJournal of Pharmacy and Pharmacology 2020; 72(11): 1528 doi: 10.1111/jphp.13333
18
Masashi Takano, Kaichiro Yamamoto, Tsutomu Tabata, Yuji Minegishi, Takuma Yokoyama, Eiji Hirata, Takeshi Ikeda, Muneaki Shimada, Kouzo Yamada, Satoshi Morita, Yuichi Ando, Koji Hirata, Masahiro Sugihara, Toru Sugiyama, Yasuo Ohashi, Yuh Sakata. Impact ofUGT1A1genotype upon toxicities of combination with low-dose irinotecan plus platinumAsia-Pacific Journal of Clinical Oncology 2016; 12(2): 115 doi: 10.1111/ajco.12453
19
Do Yoon Kim, Tae Yoon Paek, Seung Yeop Oh, Young Bae Kim, Je Hee Lee, Mi Young Lee, Zi Sun Choi, Kwang Wook Suh. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancerJournal of Surgical Oncology 2014; 109(3): 250 doi: 10.1002/jso.23500
20
Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec. UGT1A1genotype and irinotecan therapy: general review and implementation in routine practiceFundamental & Clinical Pharmacology 2015; 29(3): 219 doi: 10.1111/fcp.12117
21
M Li, E L Seiser, R M Baldwin, J Ramirez, M J Ratain, F Innocenti, D L Kroetz. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropeniaThe Pharmacogenomics Journal 2018; 18(1): 35 doi: 10.1038/tpj.2016.75
22
Jing Gao, Jun Zhou, Yanyan Li, Zhi Peng, Yilin Li, Xicheng Wang, Lin Shen. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patientsMedical Oncology 2013; 30(3) doi: 10.1007/s12032-013-0630-8
23
Fei-fei Han, Chang-long Guo, Dan Yu, Jin Zhu, Li-li Gong, Guang-run Li, Ya-li Lv, He Liu, Guang-yu An, Li-hong Liu. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patientsCancer Chemotherapy and Pharmacology 2014; 73(4): 779 doi: 10.1007/s00280-014-2405-0
24
Bettina Butzke, Fuat S. Oduncu, Franziska Severin, Arne Pfeufer, Volker Heinemann, Clemens Giessen-Jung, Björn Stollenwerk, Wolf H. Rogowski. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insuranceActa Oncologica 2016; 55(3): 318 doi: 10.3109/0284186X.2015.1053983
25
Ahmed El Bastawisy, Abeer Bahnasy, Amany El-Zeiny, Samar Farid. UGT1A1*28 Polymorphism in Advanced Colorectal Cancer: The Story Is Not Yet EndedJournal of Cancer Therapy 2014; 5(01): 53 doi: 10.4236/jct.2014.51007
26
Pierre Bohanes, Heinz-Josef Lenz. Handbook of Anticancer Pharmacokinetics and PharmacodynamicsCancer Drug Discovery and Development 2014; : 289 doi: 10.1007/978-1-4614-9135-4_17
27
Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio. Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patientsPharmacogenomics 2017; 18(6): 539 doi: 10.2217/pgs-2016-0176
28
Rodrigo Dienstmann, Eduardo Vilar, Josep Tabernero. Molecular Predictors of Response to Chemotherapy in Colorectal CancerThe Cancer Journal 2011; 17(2): 114 doi: 10.1097/PPO.0b013e318212f844
29
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancerCancer Chemotherapy and Pharmacology 2016; 78(1): 119 doi: 10.1007/s00280-016-3057-z
30
M M Dias, J-P Pignon, C S Karapetis, V Boige, B Glimelius, D M Kweekel, P N Lara, P Laurent-Puig, E Martinez-Balibrea, D Páez, C J A Punt, M W Redman, G Toffoli, M Wadelius, R A McKinnon, M J Sorich. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisThe Pharmacogenomics Journal 2014; 14(5): 424 doi: 10.1038/tpj.2014.16
31
Xiang Liu, Dangxiao Cheng, Qin Kuang, Geoffrey Liu, Wei Xu, Robert Lafrenie. Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in CaucasiansPLoS ONE 2013; 8(3): e58489 doi: 10.1371/journal.pone.0058489
32
Rodney Hull, Monde McMillan Ntwasa. Glycolytic flux occurs in Drosophila melanogaster recovering from camptothecin treatmentAnti-Cancer Drugs 2010; 21(10): 945 doi: 10.1097/CAD.0b013e32833e2f60
33
Leticia De Mattos-Arruda, Rodrigo Dienstmann, Josep Tabernero. Development of Molecular Biomarkers in Individualized Treatment of Colorectal CancerClinical Colorectal Cancer 2011; 10(4): 279 doi: 10.1016/j.clcc.2011.03.030
34
X Liu, D Cheng, Q Kuang, G Liu, W Xu. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in CaucasiansThe Pharmacogenomics Journal 2014; 14(2): 120 doi: 10.1038/tpj.2013.10
35
Daniele Mengato, Raffaella Binazzi, Ivan Unterholzner, Elke M. Erne, Alicia Tavella. Psychiatric Disorders after Switching to Dolutegravir: A Case Report of a 59-Year-Old Virosuppressed HIV-1 Positive WomanCase Reports in Infectious Diseases 2020; 2020: 1 doi: 10.1155/2020/9708913